nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—melanoma	0.358	0.689	CbGaD
Thalidomide—TNF—melanoma	0.11	0.211	CbGaD
Thalidomide—PTGS2—melanoma	0.0521	0.1	CbGaD
Thalidomide—CYP1A1—Dacarbazine—melanoma	0.0509	0.263	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—melanoma	0.0393	0.203	CbGbCtD
Thalidomide—CYP1A2—Carmustine—melanoma	0.0375	0.194	CbGbCtD
Thalidomide—CYP1A2—Vemurafenib—melanoma	0.0296	0.153	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—melanoma	0.0227	0.117	CbGbCtD
Thalidomide—CYP3A5—Docetaxel—melanoma	0.0137	0.0706	CbGbCtD
Thalidomide—FGFR2—skin epidermis—melanoma	0.00257	0.114	CbGeAlD
Thalidomide—FGFR2—neck—melanoma	0.00123	0.0545	CbGeAlD
Thalidomide—PTGS2—leg—melanoma	0.00123	0.0543	CbGeAlD
Thalidomide—NFKB1—eye—melanoma	0.00122	0.054	CbGeAlD
Thalidomide—PTGS2—hindlimb—melanoma	0.00109	0.0485	CbGeAlD
Thalidomide—Pomalidomide—TNF—melanoma	0.00102	0.354	CrCbGaD
Thalidomide—CRBN—retina—melanoma	0.00101	0.0449	CbGeAlD
Thalidomide—NFKB1—mammalian vulva—melanoma	0.000967	0.0428	CbGeAlD
Thalidomide—PTGS2—appendage—melanoma	0.000939	0.0416	CbGeAlD
Thalidomide—CYP1A1—skin epidermis—melanoma	0.00093	0.0412	CbGeAlD
Thalidomide—FGFR2—eye—melanoma	0.000915	0.0406	CbGeAlD
Thalidomide—TNF—lymph node—melanoma	0.000849	0.0376	CbGeAlD
Thalidomide—CRBN—mammalian vulva—melanoma	0.00081	0.0359	CbGeAlD
Thalidomide—FGFR2—skin of body—melanoma	0.000796	0.0353	CbGeAlD
Thalidomide—PTGS2—skin epidermis—melanoma	0.000781	0.0346	CbGeAlD
Thalidomide—NFKB1—head—melanoma	0.000692	0.0307	CbGeAlD
Thalidomide—PTGS1—endothelium—melanoma	0.000593	0.0263	CbGeAlD
Thalidomide—CRBN—head—melanoma	0.00058	0.0257	CbGeAlD
Thalidomide—PTGS2—endothelium—melanoma	0.000567	0.0251	CbGeAlD
Thalidomide—PTGS1—blood vessel—melanoma	0.000547	0.0242	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—melanoma	0.000524	0.181	CrCbGaD
Thalidomide—PTGS2—blood vessel—melanoma	0.000523	0.0232	CbGeAlD
Thalidomide—FGFR2—head—melanoma	0.000519	0.023	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—melanoma	0.000487	0.168	CrCbGaD
Thalidomide—NFKB1—lymph node—melanoma	0.000484	0.0215	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—melanoma	0.000445	0.154	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—melanoma	0.000414	0.143	CrCbGaD
Thalidomide—CRBN—lymph node—melanoma	0.000406	0.018	CbGeAlD
Thalidomide—CYP1A1—skin of body—melanoma	0.000288	0.0128	CbGeAlD
Thalidomide—CYP1A1—mammalian vulva—melanoma	0.000263	0.0116	CbGeAlD
Thalidomide—PTGS1—skin of body—melanoma	0.000253	0.0112	CbGeAlD
Thalidomide—PTGS2—skin of body—melanoma	0.000242	0.0107	CbGeAlD
Thalidomide—PTGS1—mammalian vulva—melanoma	0.000231	0.0102	CbGeAlD
Thalidomide—CYP1A1—head—melanoma	0.000188	0.00833	CbGeAlD
Thalidomide—CYP2E1—head—melanoma	0.000171	0.0076	CbGeAlD
Thalidomide—PTGS1—head—melanoma	0.000165	0.00732	CbGeAlD
Thalidomide—PTGS2—head—melanoma	0.000158	0.007	CbGeAlD
Thalidomide—CYP1A1—lymph node—melanoma	0.000132	0.00583	CbGeAlD
Thalidomide—Chills—Temozolomide—melanoma	0.000124	0.00105	CcSEcCtD
Thalidomide—Dehydration—Docetaxel—melanoma	0.000124	0.00105	CcSEcCtD
Thalidomide—Ill-defined disorder—Dactinomycin—melanoma	0.000124	0.00105	CcSEcCtD
Thalidomide—Anaemia—Dactinomycin—melanoma	0.000123	0.00105	CcSEcCtD
Thalidomide—Liver function test abnormal—Docetaxel—melanoma	0.000123	0.00104	CcSEcCtD
Thalidomide—Vomiting—Vemurafenib—melanoma	0.000123	0.00104	CcSEcCtD
Thalidomide—Alopecia—Temozolomide—melanoma	0.000123	0.00104	CcSEcCtD
Thalidomide—Dry skin—Docetaxel—melanoma	0.000122	0.00104	CcSEcCtD
Thalidomide—Chest pain—Bleomycin—melanoma	0.000122	0.00103	CcSEcCtD
Thalidomide—Myalgia—Bleomycin—melanoma	0.000122	0.00103	CcSEcCtD
Thalidomide—Orthostatic hypotension—Docetaxel—melanoma	0.000122	0.00103	CcSEcCtD
Thalidomide—Rash—Vemurafenib—melanoma	0.000122	0.00103	CcSEcCtD
Thalidomide—Mental disorder—Temozolomide—melanoma	0.000122	0.00103	CcSEcCtD
Thalidomide—Dermatitis—Vemurafenib—melanoma	0.000121	0.00103	CcSEcCtD
Thalidomide—Back pain—Carmustine—melanoma	0.000121	0.00102	CcSEcCtD
Thalidomide—Headache—Vemurafenib—melanoma	0.000121	0.00102	CcSEcCtD
Thalidomide—Malnutrition—Temozolomide—melanoma	0.000121	0.00102	CcSEcCtD
Thalidomide—Breast disorder—Docetaxel—melanoma	0.000121	0.00102	CcSEcCtD
Thalidomide—Discomfort—Bleomycin—melanoma	0.00012	0.00102	CcSEcCtD
Thalidomide—Malaise—Dactinomycin—melanoma	0.00012	0.00102	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00012	0.00102	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00012	0.00102	CcSEcCtD
Thalidomide—Cramp muscle—Docetaxel—melanoma	0.00012	0.00102	CcSEcCtD
Thalidomide—Leukopenia—Dactinomycin—melanoma	0.00012	0.00101	CcSEcCtD
Thalidomide—Dysgeusia—Temozolomide—melanoma	0.000118	0.001	CcSEcCtD
Thalidomide—Confusional state—Bleomycin—melanoma	0.000118	0.000998	CcSEcCtD
Thalidomide—Vision blurred—Carmustine—melanoma	0.000118	0.000998	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Docetaxel—melanoma	0.000118	0.000997	CcSEcCtD
Thalidomide—Tremor—Carmustine—melanoma	0.000117	0.000992	CcSEcCtD
Thalidomide—Oedema—Bleomycin—melanoma	0.000117	0.00099	CcSEcCtD
Thalidomide—Back pain—Temozolomide—melanoma	0.000117	0.00099	CcSEcCtD
Thalidomide—Infection—Bleomycin—melanoma	0.000116	0.000984	CcSEcCtD
Thalidomide—PTGS1—lymph node—melanoma	0.000116	0.00512	CbGeAlD
Thalidomide—Anaemia—Carmustine—melanoma	0.000116	0.000979	CcSEcCtD
Thalidomide—Dysphagia—Docetaxel—melanoma	0.000115	0.000977	CcSEcCtD
Thalidomide—Agitation—Carmustine—melanoma	0.000115	0.000973	CcSEcCtD
Thalidomide—Nausea—Vemurafenib—melanoma	0.000115	0.000971	CcSEcCtD
Thalidomide—Thrombocytopenia—Bleomycin—melanoma	0.000114	0.000969	CcSEcCtD
Thalidomide—Vision blurred—Temozolomide—melanoma	0.000114	0.000964	CcSEcCtD
Thalidomide—Myalgia—Dactinomycin—melanoma	0.000114	0.000963	CcSEcCtD
Thalidomide—Bronchospasm—Docetaxel—melanoma	0.000113	0.000961	CcSEcCtD
Thalidomide—Tremor—Temozolomide—melanoma	0.000113	0.000959	CcSEcCtD
Thalidomide—Discomfort—Dactinomycin—melanoma	0.000112	0.000952	CcSEcCtD
Thalidomide—Angina pectoris—Docetaxel—melanoma	0.000112	0.000951	CcSEcCtD
Thalidomide—Ill-defined disorder—Temozolomide—melanoma	0.000112	0.00095	CcSEcCtD
Thalidomide—Leukopenia—Carmustine—melanoma	0.000112	0.000948	CcSEcCtD
Thalidomide—Anaemia—Temozolomide—melanoma	0.000112	0.000946	CcSEcCtD
Thalidomide—Anorexia—Bleomycin—melanoma	0.000111	0.000944	CcSEcCtD
Thalidomide—Agitation—Temozolomide—melanoma	0.000111	0.00094	CcSEcCtD
Thalidomide—PTGS2—lymph node—melanoma	0.000111	0.0049	CbGeAlD
Thalidomide—Angioedema—Temozolomide—melanoma	0.00011	0.000935	CcSEcCtD
Thalidomide—Pancytopenia—Docetaxel—melanoma	0.000109	0.000928	CcSEcCtD
Thalidomide—Hypotension—Bleomycin—melanoma	0.000109	0.000925	CcSEcCtD
Thalidomide—Oedema—Dactinomycin—melanoma	0.000109	0.000923	CcSEcCtD
Thalidomide—Malaise—Temozolomide—melanoma	0.000109	0.000923	CcSEcCtD
Thalidomide—Vertigo—Temozolomide—melanoma	0.000108	0.000919	CcSEcCtD
Thalidomide—Convulsion—Carmustine—melanoma	0.000108	0.000918	CcSEcCtD
Thalidomide—Infection—Dactinomycin—melanoma	0.000108	0.000917	CcSEcCtD
Thalidomide—Leukopenia—Temozolomide—melanoma	0.000108	0.000916	CcSEcCtD
Thalidomide—Hypertension—Carmustine—melanoma	0.000108	0.000914	CcSEcCtD
Thalidomide—Neutropenia—Docetaxel—melanoma	0.000108	0.000913	CcSEcCtD
Thalidomide—Palpitations—Temozolomide—melanoma	0.000107	0.000904	CcSEcCtD
Thalidomide—Thrombocytopenia—Dactinomycin—melanoma	0.000107	0.000904	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000106	0.000902	CcSEcCtD
Thalidomide—Chest pain—Carmustine—melanoma	0.000106	0.000902	CcSEcCtD
Thalidomide—Myalgia—Carmustine—melanoma	0.000106	0.000902	CcSEcCtD
Thalidomide—Anxiety—Carmustine—melanoma	0.000106	0.000898	CcSEcCtD
Thalidomide—Cough—Temozolomide—melanoma	0.000105	0.000893	CcSEcCtD
Thalidomide—Paraesthesia—Bleomycin—melanoma	0.000105	0.000889	CcSEcCtD
Thalidomide—Weight increased—Docetaxel—melanoma	0.000105	0.000889	CcSEcCtD
Thalidomide—Convulsion—Temozolomide—melanoma	0.000105	0.000887	CcSEcCtD
Thalidomide—Weight decreased—Docetaxel—melanoma	0.000104	0.000884	CcSEcCtD
Thalidomide—Hypertension—Temozolomide—melanoma	0.000104	0.000884	CcSEcCtD
Thalidomide—Dyspnoea—Bleomycin—melanoma	0.000104	0.000883	CcSEcCtD
Thalidomide—Anorexia—Dactinomycin—melanoma	0.000104	0.00088	CcSEcCtD
Thalidomide—Pneumonia—Docetaxel—melanoma	0.000103	0.000876	CcSEcCtD
Thalidomide—Confusional state—Carmustine—melanoma	0.000103	0.000871	CcSEcCtD
Thalidomide—Myalgia—Temozolomide—melanoma	0.000103	0.000871	CcSEcCtD
Thalidomide—Arthralgia—Temozolomide—melanoma	0.000103	0.000871	CcSEcCtD
Thalidomide—Infestation NOS—Docetaxel—melanoma	0.000103	0.000871	CcSEcCtD
Thalidomide—Infestation—Docetaxel—melanoma	0.000103	0.000871	CcSEcCtD
Thalidomide—Anxiety—Temozolomide—melanoma	0.000102	0.000868	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000102	0.000865	CcSEcCtD
Thalidomide—Oedema—Carmustine—melanoma	0.000102	0.000864	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000102	0.000863	CcSEcCtD
Thalidomide—Discomfort—Temozolomide—melanoma	0.000102	0.000861	CcSEcCtD
Thalidomide—Decreased appetite—Bleomycin—melanoma	0.000102	0.000861	CcSEcCtD
Thalidomide—Infection—Carmustine—melanoma	0.000101	0.000859	CcSEcCtD
Thalidomide—Acute coronary syndrome—Docetaxel—melanoma	0.000101	0.000858	CcSEcCtD
Thalidomide—Renal failure—Docetaxel—melanoma	0.000101	0.000856	CcSEcCtD
Thalidomide—Myocardial infarction—Docetaxel—melanoma	0.000101	0.000854	CcSEcCtD
Thalidomide—Neuropathy peripheral—Docetaxel—melanoma	0.000101	0.000854	CcSEcCtD
Thalidomide—Dry mouth—Temozolomide—melanoma	0.000101	0.000852	CcSEcCtD
Thalidomide—Stomatitis—Docetaxel—melanoma	0.0001	0.000849	CcSEcCtD
Thalidomide—Pain—Bleomycin—melanoma	9.99e-05	0.000847	CcSEcCtD
Thalidomide—Conjunctivitis—Docetaxel—melanoma	9.99e-05	0.000846	CcSEcCtD
Thalidomide—Thrombocytopenia—Carmustine—melanoma	9.99e-05	0.000846	CcSEcCtD
Thalidomide—Tachycardia—Carmustine—melanoma	9.95e-05	0.000843	CcSEcCtD
Thalidomide—Confusional state—Temozolomide—melanoma	9.94e-05	0.000842	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dactinomycin—melanoma	9.93e-05	0.000841	CcSEcCtD
Thalidomide—Oedema—Temozolomide—melanoma	9.86e-05	0.000835	CcSEcCtD
Thalidomide—Infection—Temozolomide—melanoma	9.79e-05	0.00083	CcSEcCtD
Thalidomide—Anorexia—Carmustine—melanoma	9.72e-05	0.000824	CcSEcCtD
Thalidomide—Epistaxis—Docetaxel—melanoma	9.69e-05	0.000821	CcSEcCtD
Thalidomide—Nervous system disorder—Temozolomide—melanoma	9.67e-05	0.000819	CcSEcCtD
Thalidomide—Thrombocytopenia—Temozolomide—melanoma	9.65e-05	0.000818	CcSEcCtD
Thalidomide—Feeling abnormal—Bleomycin—melanoma	9.63e-05	0.000816	CcSEcCtD
Thalidomide—Agranulocytosis—Docetaxel—melanoma	9.59e-05	0.000813	CcSEcCtD
Thalidomide—Skin disorder—Temozolomide—melanoma	9.57e-05	0.000811	CcSEcCtD
Thalidomide—Hypotension—Carmustine—melanoma	9.53e-05	0.000808	CcSEcCtD
Thalidomide—Hyperhidrosis—Temozolomide—melanoma	9.53e-05	0.000807	CcSEcCtD
Thalidomide—Decreased appetite—Dactinomycin—melanoma	9.47e-05	0.000803	CcSEcCtD
Thalidomide—Fatigue—Dactinomycin—melanoma	9.39e-05	0.000796	CcSEcCtD
Thalidomide—Anorexia—Temozolomide—melanoma	9.39e-05	0.000796	CcSEcCtD
Thalidomide—Pain—Dactinomycin—melanoma	9.32e-05	0.00079	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Carmustine—melanoma	9.29e-05	0.000787	CcSEcCtD
Thalidomide—Urticaria—Bleomycin—melanoma	9.28e-05	0.000787	CcSEcCtD
Thalidomide—Rhinitis—Docetaxel—melanoma	9.25e-05	0.000784	CcSEcCtD
Thalidomide—Body temperature increased—Bleomycin—melanoma	9.24e-05	0.000783	CcSEcCtD
Thalidomide—Hepatitis—Docetaxel—melanoma	9.23e-05	0.000782	CcSEcCtD
Thalidomide—Insomnia—Carmustine—melanoma	9.22e-05	0.000782	CcSEcCtD
Thalidomide—Hypoaesthesia—Docetaxel—melanoma	9.18e-05	0.000778	CcSEcCtD
Thalidomide—Paraesthesia—Carmustine—melanoma	9.16e-05	0.000776	CcSEcCtD
Thalidomide—Pharyngitis—Docetaxel—melanoma	9.16e-05	0.000776	CcSEcCtD
Thalidomide—Urinary tract disorder—Docetaxel—melanoma	9.11e-05	0.000772	CcSEcCtD
Thalidomide—Dyspnoea—Carmustine—melanoma	9.09e-05	0.000771	CcSEcCtD
Thalidomide—Oedema peripheral—Docetaxel—melanoma	9.09e-05	0.00077	CcSEcCtD
Thalidomide—Somnolence—Carmustine—melanoma	9.07e-05	0.000768	CcSEcCtD
Thalidomide—Urethral disorder—Docetaxel—melanoma	9.04e-05	0.000766	CcSEcCtD
Thalidomide—Feeling abnormal—Dactinomycin—melanoma	8.98e-05	0.000761	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Temozolomide—melanoma	8.98e-05	0.000761	CcSEcCtD
Thalidomide—Insomnia—Temozolomide—melanoma	8.91e-05	0.000755	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dactinomycin—melanoma	8.91e-05	0.000755	CcSEcCtD
Thalidomide—Visual impairment—Docetaxel—melanoma	8.89e-05	0.000753	CcSEcCtD
Thalidomide—Decreased appetite—Carmustine—melanoma	8.87e-05	0.000751	CcSEcCtD
Thalidomide—Paraesthesia—Temozolomide—melanoma	8.85e-05	0.00075	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Carmustine—melanoma	8.8e-05	0.000746	CcSEcCtD
Thalidomide—Dyspnoea—Temozolomide—melanoma	8.79e-05	0.000745	CcSEcCtD
Thalidomide—Somnolence—Temozolomide—melanoma	8.76e-05	0.000742	CcSEcCtD
Thalidomide—Erythema multiforme—Docetaxel—melanoma	8.72e-05	0.000739	CcSEcCtD
Thalidomide—Pain—Carmustine—melanoma	8.72e-05	0.000739	CcSEcCtD
Thalidomide—Constipation—Carmustine—melanoma	8.72e-05	0.000739	CcSEcCtD
Thalidomide—Dyspepsia—Temozolomide—melanoma	8.68e-05	0.000735	CcSEcCtD
Thalidomide—Eye disorder—Docetaxel—melanoma	8.62e-05	0.000731	CcSEcCtD
Thalidomide—Abdominal pain—Dactinomycin—melanoma	8.61e-05	0.00073	CcSEcCtD
Thalidomide—Body temperature increased—Dactinomycin—melanoma	8.61e-05	0.00073	CcSEcCtD
Thalidomide—Hypersensitivity—Bleomycin—melanoma	8.61e-05	0.000729	CcSEcCtD
Thalidomide—Decreased appetite—Temozolomide—melanoma	8.57e-05	0.000726	CcSEcCtD
Thalidomide—Cardiac disorder—Docetaxel—melanoma	8.56e-05	0.000726	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Temozolomide—melanoma	8.51e-05	0.000721	CcSEcCtD
Thalidomide—Fatigue—Temozolomide—melanoma	8.5e-05	0.00072	CcSEcCtD
Thalidomide—Pain—Temozolomide—melanoma	8.43e-05	0.000714	CcSEcCtD
Thalidomide—Constipation—Temozolomide—melanoma	8.43e-05	0.000714	CcSEcCtD
Thalidomide—Feeling abnormal—Carmustine—melanoma	8.4e-05	0.000712	CcSEcCtD
Thalidomide—Asthenia—Bleomycin—melanoma	8.38e-05	0.00071	CcSEcCtD
Thalidomide—Angiopathy—Docetaxel—melanoma	8.37e-05	0.000709	CcSEcCtD
Thalidomide—Gastrointestinal pain—Carmustine—melanoma	8.34e-05	0.000707	CcSEcCtD
Thalidomide—Immune system disorder—Docetaxel—melanoma	8.33e-05	0.000706	CcSEcCtD
Thalidomide—Mediastinal disorder—Docetaxel—melanoma	8.31e-05	0.000705	CcSEcCtD
Thalidomide—Chills—Docetaxel—melanoma	8.28e-05	0.000701	CcSEcCtD
Thalidomide—Pruritus—Bleomycin—melanoma	8.27e-05	0.0007	CcSEcCtD
Thalidomide—Arrhythmia—Docetaxel—melanoma	8.24e-05	0.000698	CcSEcCtD
Thalidomide—Alopecia—Docetaxel—melanoma	8.15e-05	0.000691	CcSEcCtD
Thalidomide—Feeling abnormal—Temozolomide—melanoma	8.12e-05	0.000688	CcSEcCtD
Thalidomide—Mental disorder—Docetaxel—melanoma	8.08e-05	0.000685	CcSEcCtD
Thalidomide—Abdominal pain—Carmustine—melanoma	8.06e-05	0.000683	CcSEcCtD
Thalidomide—Body temperature increased—Carmustine—melanoma	8.06e-05	0.000683	CcSEcCtD
Thalidomide—Gastrointestinal pain—Temozolomide—melanoma	8.06e-05	0.000683	CcSEcCtD
Thalidomide—Malnutrition—Docetaxel—melanoma	8.03e-05	0.000681	CcSEcCtD
Thalidomide—Hypersensitivity—Dactinomycin—melanoma	8.03e-05	0.00068	CcSEcCtD
Thalidomide—Dysgeusia—Docetaxel—melanoma	7.86e-05	0.000666	CcSEcCtD
Thalidomide—Urticaria—Temozolomide—melanoma	7.83e-05	0.000663	CcSEcCtD
Thalidomide—Asthenia—Dactinomycin—melanoma	7.82e-05	0.000663	CcSEcCtD
Thalidomide—Abdominal pain—Temozolomide—melanoma	7.79e-05	0.00066	CcSEcCtD
Thalidomide—Body temperature increased—Temozolomide—melanoma	7.79e-05	0.00066	CcSEcCtD
Thalidomide—Back pain—Docetaxel—melanoma	7.77e-05	0.000658	CcSEcCtD
Thalidomide—Muscle spasms—Docetaxel—melanoma	7.72e-05	0.000654	CcSEcCtD
Thalidomide—Hypersensitivity—Carmustine—melanoma	7.51e-05	0.000637	CcSEcCtD
Thalidomide—Diarrhoea—Dactinomycin—melanoma	7.46e-05	0.000632	CcSEcCtD
Thalidomide—Vomiting—Bleomycin—melanoma	7.43e-05	0.00063	CcSEcCtD
Thalidomide—Anaemia—Docetaxel—melanoma	7.42e-05	0.000629	CcSEcCtD
Thalidomide—Rash—Bleomycin—melanoma	7.37e-05	0.000624	CcSEcCtD
Thalidomide—Dermatitis—Bleomycin—melanoma	7.36e-05	0.000624	CcSEcCtD
Thalidomide—Asthenia—Carmustine—melanoma	7.32e-05	0.00062	CcSEcCtD
Thalidomide—Hypersensitivity—Temozolomide—melanoma	7.26e-05	0.000615	CcSEcCtD
Thalidomide—Syncope—Docetaxel—melanoma	7.2e-05	0.00061	CcSEcCtD
Thalidomide—Leukopenia—Docetaxel—melanoma	7.19e-05	0.000609	CcSEcCtD
Thalidomide—Palpitations—Docetaxel—melanoma	7.1e-05	0.000601	CcSEcCtD
Thalidomide—Asthenia—Temozolomide—melanoma	7.07e-05	0.000599	CcSEcCtD
Thalidomide—Loss of consciousness—Docetaxel—melanoma	7.06e-05	0.000598	CcSEcCtD
Thalidomide—Cough—Docetaxel—melanoma	7.01e-05	0.000594	CcSEcCtD
Thalidomide—Diarrhoea—Carmustine—melanoma	6.98e-05	0.000591	CcSEcCtD
Thalidomide—Pruritus—Temozolomide—melanoma	6.97e-05	0.000591	CcSEcCtD
Thalidomide—Convulsion—Docetaxel—melanoma	6.96e-05	0.00059	CcSEcCtD
Thalidomide—Nausea—Bleomycin—melanoma	6.94e-05	0.000588	CcSEcCtD
Thalidomide—Hypertension—Docetaxel—melanoma	6.93e-05	0.000588	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—melanoma	6.93e-05	0.000587	CcSEcCtD
Thalidomide—Rash—Dactinomycin—melanoma	6.87e-05	0.000582	CcSEcCtD
Thalidomide—Arthralgia—Docetaxel—melanoma	6.84e-05	0.000579	CcSEcCtD
Thalidomide—Chest pain—Docetaxel—melanoma	6.84e-05	0.000579	CcSEcCtD
Thalidomide—Myalgia—Docetaxel—melanoma	6.84e-05	0.000579	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	6.79e-05	0.000575	CcSEcCtD
Thalidomide—Dizziness—Carmustine—melanoma	6.74e-05	0.000572	CcSEcCtD
Thalidomide—Diarrhoea—Temozolomide—melanoma	6.74e-05	0.000571	CcSEcCtD
Thalidomide—Dry mouth—Docetaxel—melanoma	6.69e-05	0.000567	CcSEcCtD
Thalidomide—Confusional state—Docetaxel—melanoma	6.61e-05	0.00056	CcSEcCtD
Thalidomide—Oedema—Docetaxel—melanoma	6.55e-05	0.000555	CcSEcCtD
Thalidomide—Dizziness—Temozolomide—melanoma	6.52e-05	0.000552	CcSEcCtD
Thalidomide—Infection—Docetaxel—melanoma	6.51e-05	0.000552	CcSEcCtD
Thalidomide—Vomiting—Carmustine—melanoma	6.48e-05	0.00055	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—melanoma	6.47e-05	0.000548	CcSEcCtD
Thalidomide—Shock—Docetaxel—melanoma	6.45e-05	0.000546	CcSEcCtD
Thalidomide—Rash—Carmustine—melanoma	6.43e-05	0.000545	CcSEcCtD
Thalidomide—Nervous system disorder—Docetaxel—melanoma	6.43e-05	0.000545	CcSEcCtD
Thalidomide—Dermatitis—Carmustine—melanoma	6.42e-05	0.000544	CcSEcCtD
Thalidomide—Thrombocytopenia—Docetaxel—melanoma	6.42e-05	0.000544	CcSEcCtD
Thalidomide—Tachycardia—Docetaxel—melanoma	6.4e-05	0.000542	CcSEcCtD
Thalidomide—Headache—Carmustine—melanoma	6.39e-05	0.000541	CcSEcCtD
Thalidomide—Skin disorder—Docetaxel—melanoma	6.37e-05	0.000539	CcSEcCtD
Thalidomide—Vomiting—Temozolomide—melanoma	6.27e-05	0.000531	CcSEcCtD
Thalidomide—Anorexia—Docetaxel—melanoma	6.25e-05	0.000529	CcSEcCtD
Thalidomide—Rash—Temozolomide—melanoma	6.21e-05	0.000527	CcSEcCtD
Thalidomide—Dermatitis—Temozolomide—melanoma	6.21e-05	0.000526	CcSEcCtD
Thalidomide—Headache—Temozolomide—melanoma	6.17e-05	0.000523	CcSEcCtD
Thalidomide—Hypotension—Docetaxel—melanoma	6.12e-05	0.000519	CcSEcCtD
Thalidomide—Nausea—Carmustine—melanoma	6.06e-05	0.000513	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Docetaxel—melanoma	5.97e-05	0.000506	CcSEcCtD
Thalidomide—Insomnia—Docetaxel—melanoma	5.93e-05	0.000502	CcSEcCtD
Thalidomide—Paraesthesia—Docetaxel—melanoma	5.89e-05	0.000499	CcSEcCtD
Thalidomide—Nausea—Temozolomide—melanoma	5.85e-05	0.000496	CcSEcCtD
Thalidomide—Dyspnoea—Docetaxel—melanoma	5.84e-05	0.000495	CcSEcCtD
Thalidomide—Somnolence—Docetaxel—melanoma	5.83e-05	0.000494	CcSEcCtD
Thalidomide—Dyspepsia—Docetaxel—melanoma	5.77e-05	0.000489	CcSEcCtD
Thalidomide—Decreased appetite—Docetaxel—melanoma	5.7e-05	0.000483	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—melanoma	5.66e-05	0.00048	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—melanoma	5.65e-05	0.000479	CcSEcCtD
Thalidomide—Pain—Docetaxel—melanoma	5.6e-05	0.000475	CcSEcCtD
Thalidomide—Constipation—Docetaxel—melanoma	5.6e-05	0.000475	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—melanoma	5.4e-05	0.000458	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—melanoma	5.36e-05	0.000454	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—melanoma	5.18e-05	0.000439	CcSEcCtD
Thalidomide—Body temperature increased—Docetaxel—melanoma	5.18e-05	0.000439	CcSEcCtD
Thalidomide—Hypersensitivity—Docetaxel—melanoma	4.83e-05	0.000409	CcSEcCtD
Thalidomide—Asthenia—Docetaxel—melanoma	4.7e-05	0.000398	CcSEcCtD
Thalidomide—Pruritus—Docetaxel—melanoma	4.64e-05	0.000393	CcSEcCtD
Thalidomide—Diarrhoea—Docetaxel—melanoma	4.48e-05	0.00038	CcSEcCtD
Thalidomide—Dizziness—Docetaxel—melanoma	4.33e-05	0.000367	CcSEcCtD
Thalidomide—Vomiting—Docetaxel—melanoma	4.17e-05	0.000353	CcSEcCtD
Thalidomide—Rash—Docetaxel—melanoma	4.13e-05	0.00035	CcSEcCtD
Thalidomide—Dermatitis—Docetaxel—melanoma	4.13e-05	0.00035	CcSEcCtD
Thalidomide—Headache—Docetaxel—melanoma	4.11e-05	0.000348	CcSEcCtD
Thalidomide—Nausea—Docetaxel—melanoma	3.89e-05	0.00033	CcSEcCtD
Thalidomide—NFKB1—Immune System—MAPK1—melanoma	3.01e-06	2.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—melanoma	3.01e-06	2.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK3—melanoma	3e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP17A1—melanoma	2.96e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.92e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.92e-06	2.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—melanoma	2.9e-06	2.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—melanoma	2.89e-06	2.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGF2—melanoma	2.89e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—melanoma	2.89e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—melanoma	2.89e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	2.88e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAC1—melanoma	2.88e-06	2.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—melanoma	2.86e-06	1.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—melanoma	2.86e-06	1.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MDM2—melanoma	2.85e-06	1.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—melanoma	2.84e-06	1.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—melanoma	2.83e-06	1.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—melanoma	2.81e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNA11—melanoma	2.8e-06	1.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK3—melanoma	2.77e-06	1.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CB—melanoma	2.77e-06	1.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—melanoma	2.76e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FASN—melanoma	2.74e-06	1.91e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—VCAN—melanoma	2.74e-06	1.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MDM2—melanoma	2.7e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP17A1—melanoma	2.7e-06	1.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—melanoma	2.7e-06	1.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—melanoma	2.7e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC5A5—melanoma	2.69e-06	1.88e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.69e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.69e-06	1.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—melanoma	2.66e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.66e-06	1.86e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—melanoma	2.66e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—melanoma	2.66e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—melanoma	2.66e-06	1.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—melanoma	2.64e-06	1.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—melanoma	2.64e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	2.63e-06	1.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CB—melanoma	2.63e-06	1.83e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—melanoma	2.61e-06	1.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PRKCA—melanoma	2.6e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAQ—melanoma	2.6e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD44—melanoma	2.6e-06	1.81e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—melanoma	2.6e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.59e-06	1.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ERCC2—melanoma	2.58e-06	1.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—melanoma	2.57e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNA11—melanoma	2.55e-06	1.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—melanoma	2.55e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.55e-06	1.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—melanoma	2.54e-06	1.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—melanoma	2.53e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.52e-06	1.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—melanoma	2.51e-06	1.75e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—melanoma	2.51e-06	1.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.5e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FASN—melanoma	2.5e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1B1—melanoma	2.49e-06	1.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—melanoma	2.49e-06	1.74e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—melanoma	2.49e-06	1.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—melanoma	2.48e-06	1.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—melanoma	2.48e-06	1.73e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—melanoma	2.48e-06	1.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—melanoma	2.47e-06	1.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—melanoma	2.46e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC5A5—melanoma	2.46e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PRKCA—melanoma	2.45e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PRKCA—melanoma	2.44e-06	1.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD80—melanoma	2.44e-06	1.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—melanoma	2.43e-06	1.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—melanoma	2.43e-06	1.7e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ERCC2—melanoma	2.43e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ERCC2—melanoma	2.42e-06	1.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—melanoma	2.42e-06	1.69e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—melanoma	2.42e-06	1.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—melanoma	2.41e-06	1.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—melanoma	2.41e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGF—melanoma	2.41e-06	1.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—melanoma	2.4e-06	1.67e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—melanoma	2.39e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAQ—melanoma	2.37e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD44—melanoma	2.37e-06	1.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—melanoma	2.35e-06	1.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—melanoma	2.33e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.32e-06	1.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—melanoma	2.31e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PRKCA—melanoma	2.31e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP17A1—melanoma	2.31e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.3e-06	1.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—melanoma	2.29e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ERCC2—melanoma	2.29e-06	1.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—melanoma	2.29e-06	1.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—melanoma	2.29e-06	1.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—melanoma	2.29e-06	1.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—melanoma	2.28e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.28e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1B1—melanoma	2.27e-06	1.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—melanoma	2.27e-06	1.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—melanoma	2.26e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—melanoma	2.26e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	2.25e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—melanoma	2.23e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.2e-06	1.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—melanoma	2.19e-06	1.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNA11—melanoma	2.18e-06	1.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—melanoma	2.16e-06	1.51e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAP2K1—melanoma	2.15e-06	1.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—melanoma	2.14e-06	1.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—melanoma	2.13e-06	1.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FASN—melanoma	2.13e-06	1.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—melanoma	2.12e-06	1.48e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—melanoma	2.1e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—melanoma	2.05e-06	1.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—melanoma	2.05e-06	1.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—melanoma	2.05e-06	1.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—melanoma	2.05e-06	1.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—melanoma	2.04e-06	1.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—melanoma	2.03e-06	1.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAQ—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD44—melanoma	2.03e-06	1.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—melanoma	2.02e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.01e-06	1.4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—melanoma	1.99e-06	1.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.98e-06	1.38e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—melanoma	1.97e-06	1.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—melanoma	1.97e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.97e-06	1.37e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—melanoma	1.95e-06	1.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—melanoma	1.95e-06	1.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—melanoma	1.95e-06	1.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1B1—melanoma	1.94e-06	1.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—melanoma	1.94e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—melanoma	1.92e-06	1.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—melanoma	1.92e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—melanoma	1.91e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.9e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRKCA—melanoma	1.89e-06	1.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—melanoma	1.89e-06	1.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—melanoma	1.89e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ERCC2—melanoma	1.87e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—melanoma	1.87e-06	1.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—melanoma	1.87e-06	1.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—melanoma	1.86e-06	1.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—melanoma	1.86e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—melanoma	1.85e-06	1.29e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—melanoma	1.85e-06	1.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—melanoma	1.85e-06	1.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—melanoma	1.85e-06	1.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—melanoma	1.84e-06	1.28e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—melanoma	1.81e-06	1.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—melanoma	1.79e-06	1.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—melanoma	1.77e-06	1.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—melanoma	1.75e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—melanoma	1.75e-06	1.22e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—melanoma	1.74e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRKCA—melanoma	1.72e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.71e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ERCC2—melanoma	1.71e-06	1.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—melanoma	1.7e-06	1.19e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—melanoma	1.69e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—melanoma	1.69e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—melanoma	1.68e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—melanoma	1.66e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—melanoma	1.66e-06	1.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—melanoma	1.65e-06	1.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—melanoma	1.63e-06	1.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—melanoma	1.61e-06	1.13e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—melanoma	1.61e-06	1.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—melanoma	1.6e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—melanoma	1.6e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—melanoma	1.59e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—melanoma	1.57e-06	1.09e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—melanoma	1.56e-06	1.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—melanoma	1.56e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.55e-06	1.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—melanoma	1.55e-06	1.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—melanoma	1.5e-06	1.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—melanoma	1.48e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—melanoma	1.48e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRKCA—melanoma	1.47e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—melanoma	1.47e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—melanoma	1.47e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ERCC2—melanoma	1.46e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—melanoma	1.46e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—melanoma	1.45e-06	1.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—melanoma	1.44e-06	1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—melanoma	1.44e-06	1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—melanoma	1.43e-06	9.96e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—melanoma	1.42e-06	9.9e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.42e-06	9.87e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—melanoma	1.39e-06	9.67e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—melanoma	1.38e-06	9.62e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—melanoma	1.38e-06	9.6e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—melanoma	1.37e-06	9.58e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—melanoma	1.35e-06	9.41e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—melanoma	1.35e-06	9.41e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—melanoma	1.34e-06	9.34e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—melanoma	1.31e-06	9.14e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—melanoma	1.31e-06	9.13e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—melanoma	1.31e-06	9.13e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—melanoma	1.3e-06	9.08e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—melanoma	1.3e-06	9.07e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—melanoma	1.28e-06	8.96e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—melanoma	1.27e-06	8.86e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—melanoma	1.27e-06	8.84e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—melanoma	1.24e-06	8.63e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.21e-06	8.44e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—melanoma	1.2e-06	8.36e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—melanoma	1.2e-06	8.35e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—melanoma	1.19e-06	8.27e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—melanoma	1.17e-06	8.17e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—melanoma	1.15e-06	8.04e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—melanoma	1.14e-06	7.93e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—melanoma	1.13e-06	7.91e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—melanoma	1.12e-06	7.84e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—melanoma	1.11e-06	7.76e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—melanoma	1.05e-06	7.33e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—melanoma	1.03e-06	7.21e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—melanoma	1.02e-06	7.15e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—melanoma	1.01e-06	7.07e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—melanoma	1.01e-06	7.02e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—melanoma	1e-06	6.98e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—melanoma	9.8e-07	6.83e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—melanoma	9.79e-07	6.83e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—melanoma	9.52e-07	6.64e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—melanoma	9.28e-07	6.48e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—melanoma	8.96e-07	6.25e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—melanoma	8.94e-07	6.24e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—melanoma	8.93e-07	6.23e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—melanoma	8.84e-07	6.16e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—melanoma	8.75e-07	6.11e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—melanoma	8.45e-07	5.89e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—melanoma	7.78e-07	5.42e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—melanoma	7.64e-07	5.33e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—melanoma	7.32e-07	5.11e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—melanoma	7.3e-07	5.09e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—melanoma	6.91e-07	4.82e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—melanoma	6.9e-07	4.81e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—melanoma	6.3e-07	4.4e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—melanoma	5.65e-07	3.94e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—melanoma	5.39e-07	3.76e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—melanoma	5.15e-07	3.59e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—melanoma	4.4e-07	3.07e-06	CbGpPWpGaD
